Ezabenlimab with induction chemotherapy and adaptive chemoradiotherapy in stage 3 squamous cell anal carcinoma – Authors' reply

Key Points

• Ezabenlimab treatment improves tumor response in stage 3 squamous cell anal carcinoma.
• Observations indicate enhanced outcomes with induction chemotherapy and adaptive chemoradiotherapy.
• Adaptive chemoradiotherapy was utilized to tailor treatment based on individual tumor responses.
• Potential implications highlight improved management strategies for advanced anal carcinoma patients.